Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 26, 2015 1:16 AM ET

Biotechnology

Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor 2b and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fus...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

123 Employees

Phone:

415-365-5600

Fax:

415-365-5601

Key Executives for Five Prime Therapeutics, Inc.

Founder, Chief Executive Officer, President and Director
Age: 65
Total Annual Compensation: $525.0K
Chief Business Officer, Senior Vice President and Director
Age: 45
Total Annual Compensation: $362.8K
Chief Medical Officer and Senior Vice President
Age: 56
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

Five Prime Therapeutics, Inc. Key Developments

Five Prime Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Cash Flow Guidance for the Full Year 2015

Five Prime Therapeutics, Inc. reported earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $4,645,000 against $3,785,000 a year ago. Loss from operations was $11,894,000 against $7,334,000 a year ago. Net loss was $11,826,000 or $0.55 per basic and diluted share against $7,317,000 or $0.43 per basic and diluted share a year ago. Collaboration revenue for the fourth quarter of 2014 increased by $0.8 million primarily due to revenue recognized under the immuno-oncology research collaboration with BMS. For the full year, the company reported collaboration revenue of $19,231,000 against $13,791,000 a year ago. Loss from operations was $37,574,000 against $29,421,000 a year ago. Net loss was $37,424,000 or $1.79 per basic and diluted share against $28,872,000 or $5.23 per basic and diluted share a year ago. This increase in net loss was primarily related to advancing the FPA144 program into a phase 1 clinical trial and expanding internal immuno-oncology discovery efforts. Collaboration revenue for the full year 2014 increased by $5.4 million primarily due to revenue recognized under the collaborations with UCB, GSK, and BMS. The company expects full year 2015 net cash used in operating activities to be less than $65 million and estimates ending 2015 with more than $160 million in cash, cash equivalents and marketable securities.

Five Prime Therapeutics, Inc. to Report Q4, 2014 Results on Mar 17, 2015

Five Prime Therapeutics, Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 17, 2015

Five Prime Therapeutics, Inc., Q4 2014 Earnings Call, Mar 17, 2015

Five Prime Therapeutics, Inc., Q4 2014 Earnings Call, Mar 17, 2015

Similar Private Companies By Industry

Company Name Region
Meridian Life Science, Inc. United States
DelSite Biotechnologies Inc. United States
Immuno Concepts N.A. Ltd. United States
Scigenics, Inc. United States
ZaBeCor Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.